News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
LUXEMBOURG, August 14, 2026--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse …
Sharemaestro market context Trend signal active 52 weeks +7.1% · Next-week setup negative 44.7%Euroseas Ltd. reported strong financial results for Q2 2026, including a net profit of $32.6 million and an increase in Adjusted basic EPS to $9.45 for the first half of the year. The company declared a quarterly dividend of $0.80 per share and highlighted …
Chardan Capital has reiterated its Buy rating for ProMIS Neurosciences (PMN.US) and increased its price target to $33. This positive outlook suggests continued confidence in the company's prospects.
EuroDry (NASDAQ:EDRY) saw a significant increase in short interest, rising by 154.5% to 11,188 shares by July 31st, although this represents only 0.4% of outstanding shares. The company recently reported a strong quarterly earnings beat, with EPS of $2.44 against a $1.23 consensus, and …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Keurig Dr Pepper stock has gained 12.2% year to date, yet valuation checks still lean expensive and leave investors weighing recent momentum against a weak …
Sharemaestro market context Trend signal active 52 weeks -8.2%Neurocrine's drug, Vykat XR, designed to treat the insatiable appetite associated with Prader-Willi Syndrome (PWS), is facing safety warnings following seven deaths. Patient organizations and doctors are calling for more research into the drug's safety, emphasizing that PWS patients often have multiple other health …
Zacks Research has downgraded Minerva Neurosciences (NASDAQ:NERV) to a "strong sell" rating, citing weak earnings forecasts despite the company beating Q2 analyst expectations. The biopharmaceutical company's shares opened at $3.92, significantly below its 52-week high, and institutional investors hold a 34.56% stake. Analysts project …
Coeur Mining (NYSE:CDE) just delivered the biggest quarter in its history on August 6. Quarterly revenue crossed $1 billion for the first time, powered by the first full quarter of contributions from the newly acquired New Afton and Rainy River mines. Free cash flow …
Neuronetics, Inc. (NASDAQ:STIM) recently reported quarterly results showing better-than-expected revenues of US$42m and smaller statutory losses of US$0.05 per share. Analysts have largely maintained revenue forecasts for 2026 at US$161.8m but significantly reduced loss per share estimates to US$0.35. The average price target has …
Minerva Neurosciences, Inc (NASDAQ:NERV) has received a "Reduce" consensus rating from brokerages, with an average 12-month price target of $10.50. This comes as near-term earnings expectations have significantly deteriorated, with HC Wainwright cutting its fiscal 2026 and 2027 EPS estimates, although it projects profitability …
Balyasny Asset Management L.P. and its affiliates have reported a beneficial ownership of 9.99% in Minerva Neurosciences, Inc. (NERV). This stake comprises 4,654,212 shares, including 4,257,000 shares held directly by Atlas Private Holdings (Cayman) Ltd. and 397,212 shares exercisable from 13,500 warrants. The warrants …
Image source: The Motley Fool. DATE Monday, Aug. 10, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Financial Officer - Anastasios AslidisFinance Manager - Athina Atalioti TAKEAWAYS Total Net Revenues -- $17.7 million for the second quarter, representing a 57% increase compared to the …
Coeur Mining (NYSE: CDE) has significantly outperformed the market over the last five years, with an annualized return of 23.21%. An initial investment of $1000 in Coeur Mining stock five years ago would now be worth $2,781.07. This growth highlights the power of compounded …
ProMIS Neurosciences (PMN) reported strong Q2 2026 earnings call highlights, emphasizing zero ARIA-E cases and promising biomarker signals in its Phase 1b PRECISE-AD trial. The company maintains a strong cash position of $53.4 million, funding operations through 2027, and is advancing its pipeline candidates …
Keurig Dr Pepper has recently reported second-quarter 2026 results showing sales of US$7.31 billion and net income of US$142 million, while rolling out a lime-led reformulation of 7UP and partnering with Portillo's on limited-time Dr Pepper shakes in the U.S. Alongside these product moves, …
Sharemaestro market context Trend signal active 52 weeks -8.2%Eureka Acquisition Corp (EURK) has issued an $8,253 extension note to Marine Thinking Inc. to prolong the deadline for its initial business combination by one month, until September 3, 2026. Marine Thinking funded the monthly extension fee of $8,253.03, and in return, received an …
This article from Stock Traders Daily analyzes Clearpoint Neuro, Inc. (NASDAQ: CLPT) focusing on its price dynamics and execution-aware positioning. It identifies a strong near-term sentiment despite broader weak alignment, highlighting an exceptional 142.5:1 risk-reward setup targeting a 44.2% gain. The analysis provides specific …
Two healthcare companies, Alto Neuroscience, Inc. (ANRO) and Owlet (OWLT), recently received bullish ratings from analysts. Myles Minter from William Blair reiterated a Buy rating for Alto Neuroscience, with a consensus price target of $35.71. Jonna Kim from TD Cowen also reiterated a Buy …
XBP Global Holdings (NASDAQ: XBP) reported Q2 EPS of $-1.420, missing analyst estimates by $0.01, and revenue of $191.31M, falling short of the consensus estimate of $200.1M. Despite the miss, the company's stock price has risen 35.850% in the last three months, though it …
UBS analyst Sanjeet Auija downgraded Coca-Cola Europacific Partners PLC (CCEP) from Buy to Neutral, lowering the price target to $107.00 from $109.00 due to a cautious outlook. Despite a strong GF Score of 85/100, CCEP is considered 5.9% overvalued by GuruFocus, though its P/E …
Keurig Dr Pepper has appointed Aaron Alt to its Board of Directors, effective August 14, as the company prepares to separate into two standalone businesses. Alt, currently CFO of Cardinal Health, brings extensive financial and operational experience and will also join KDP's Audit and …
Promis Neurosciences (NASDAQ:PMN) reported its quarterly earnings, beating analyst estimates by $0.10 with a loss of $1.28 per share. The company highlighted encouraging interim safety results for its Alzheimer's candidate PMN310, with promising biomarker data suggesting target engagement. Promis Neurosciences expects its current cash …
ProMIS Neurosciences reported a strong cash position of CAD 53.4 million at the end of Q2 2026, sufficient to fund operations through 2027 and a crucial data readout in Q1 2027. The clinical-stage biotech company shared positive interim safety and biomarker data from its …
Farallon Capital Management, L.L.C., along with associated investment partnerships and individuals, has disclosed a 9.7% beneficial ownership in Minerva Neurosciences (NERV). This stake comprises 4,730,000 shares of common stock, including 2,365,000 directly held common shares and shares acquirable through 5,000 Preferred Tranche A Warrants. …
Search by ticker symbol or company name and select a result to open its chart.